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Abstract 
Background: Recently, genetic studies have suggested a causal relationship between cholesterol remnants and 
ischemic heart disease. We aimed to determine whether cholesterol remnants and its marker, triglyceride levels, are 
associated with cardiac function as determined by sensitive echocardiographic measures in a population of patients 
with type 2 diabetes.
Methods: Comprehensive echocardiography including 2D‑speckle tracking echocardiography was performed on 
a representative sample of 924 patients with type 2 diabetes—730 of whom were treated with statins. These were 
recruited from two large secondary care centers.
Results: In multivariable analyses, triglycerides and cholesterol remnants were not associated with left ventricular 
ejection fraction, but with subtle measures of systolic function, including global longitudinal strain by speckle track‑
ing and longitudinal displacement by tissue Doppler echocardiography: global longitudinal strain [0.33 % (0.14), 
p = 0.02 per doubling in cholesterol remnants and 0.28 % (0.13), p = 0.03 per doubling in triglyceride levels] and with 
longitudinal displacement [−0.25 mm (0.10), p = 0.01 per doubling in cholesterol remnants and −0.25 mm (0.09), 
p = 0.005 per doubling in triglyceride levels]. Subgroup analyses of patients receiving statin therapy and patients 
without known heart disease revealed similar results, but the association was not present in patients with known 
heart disease.
Conclusion: In patients with type 2 diabetes, subtle decrease in left ventricular function is present with increas‑
ing levels of cholesterol remnants and triglyceride levels indicating an effect of these on cardiac function that is not 
detectable by conventional echocardiography.
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Background
In patients with type 2 diabetes, advances in medical treat-
ment—including aggressive lipid-lowering therapy with 
statins and life-style interventions—have led to a decrease 
in mortality from cardiovascular disease [1–3]. However, 
patients with type 2 diabetes are still prone to cardiovas-
cular disease and with an increasing number of patients 
with type 2 diabetes, the burden of cardiovascular disease 
persists [4]. The residual risk may in part be attribut-
able to lipoproteins other than LDL-cholesterols that are 
the target of statin therapy, and recently, genetic studies 
have suggested a causal relationship between cholesterol 
remnants and ischemic heart disease [5, 6]. Cholesterol 
remnants—defined as cholesterol content of the larg-
est, triglyceride-rich proteins, VLDL, IDL and chylomi-
crons—are reversely related to HDL cholesterol and have 
gained renewed interest in the light of the disappointing 
results of therapies aimed at HDL cholesterol.
Remnant cholesterol possibly exerts its effect on the 
diabetic myocardium by at least 2 mechanisms. First, the 
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remnant lipoproteins can enter the intima of the coro-
nary arteries causing accumulation of cholesterol [7, 8] 
ultimately leading to at least partly obstructive disease 
affecting mainly the subendocardial myocardial fibers 
that are most susceptible to decreased coronary flow 
and are the main myocardial fibers responsible for left 
ventricular longitudinal function [9]. Second, action of 
the enzyme lipoprotein lipase on the surface of the rem-
nant particle leads to liberation of free fatty acids in the 
proximity of the myocardial cells [10] which can lead to 
accumulation of free fatty acids and triglycerides in the 
myocytes. Here, the substrate of metabolism is altered to 
almost complete reliance of fatty acids, which in turn by 
complex pathways is thought to lead to diabetic cardio-
myopathy [11, 12]. In accordance, triglycerides—which 
are markers of cholesterol remnants [6, 13]—have been 
shown to predict heart failure in patients with diabetes, 
but not in patients without diabetes [14, 15].
While cholesterol remnants are considered a risk fac-
tor for ischemic heart disease, their relation to myocar-
dial structure and function is unknown. Therefore, we 
examined the effect of cholesterol remnants and triglyc-
erides on myocardial structure and function in a popula-
tion of patients with type 2 diabetes using comprehensive 
echocardiography including 2D speckle tracking echo-
cardiography. This is a sensitive method used to identify 
subtle changes in cardiac function that we have shown 
to be reduced in patients with type 2 diabetes [16] and 
has been shown to predict cardiovascular events in these 
patients [17]. In addition, to address if statin treatment 
modifies the association of cholesterol remnants and tri-
glyceride with myocardial structure and function, we per-
formed a subgroup analysis on patients already receiving 
statin therapy.
Methods
The Thousand & 2 echocardiographic study was initi-
ated in 2011, where a representative sample of patients 
from two large secondary care centers (The Steno Dia-
betes Center and Center for Diabetes Research, Herlev 
and Gentofte Hospital, University of Copenhagen) in the 
Copenhagen region were invited to participate. Details 
are described elsewhere [18]. In brief, from November 
2011 through to December 2013, 2158 patients were 
invited and 1030 participated (participation rate 47.8 %). 
Prior to the study visit, a questionnaire was sent to the 
patients with among others questions on current medi-
cation, prior heart disease (myocardial infarction, percu-
taneous coronary intervention, coronary artery bypass 
grafting, congestive heart failure and atrial fibrillation), 
prior stroke and peripheral artery disease, family his-
tory of coronary heart disease, smoking habits, height 
and weight. At the visit, the questionnaire was reviewed 
with the patient by PGJ. In the present study, we excluded 
patients with atrial fibrillation during the echocardio-
graphic examination and/or severe valve disease/pre-
vious heart valve surgery (n  =  96) as well as patients 
where neither cholesterol remnants nor triglyceride lev-
els (n = 10) were available. Blood pressure was measured 
in the supine position after at least 15 min of rest. Body 
mass index (BMI) was defined as weight (kg)/height (m)2.
Cholesterol remnants and triglyceride
LDL-cholesterol, HDL-cholesterol and total-cholesterol 
were measured in routine blood samples using stand-
ard hospitals assays at each visit at Center for Diabetes 
research, Herlev and Gentofte Hospital, University of 
Copenhagen or at the visit at Steno Diabetes Center pre-
ceding the study visit. In Denmark, non-fasting measure-
ments of lipids is the standard, however, in a subset of the 
patients (14 %), only fasting lipids were available. Direct 
measurement of cholesterol remnants is difficult, but a 
simple approximation was obtained by calculating the 
sum of VLDL, IDL and chylomicrons with the formula 
cholesterol remnants = total-cholesterol − HDL-choles-
terol  −  LDL-cholesterol. This method is easy with the 
use of standard lipid measurements and has been used in 
previous studies [5, 6, 13, 19].
Other laboratory analyses
Hemoglobin A1c and creatinine levels were obtained 
from routine blood samples at either center as decribed 
above. Urine albumin/creatinine ratio or 24 h urine albu-
min excretion rate is performed at least annually at both 
centers. Microalbuminuria was defined as urine albumin/
creatinine ratio between 30 and 300 mg/g or urine albu-
min excretion rate between 30 and 300 mg/day, and mac-
roalbuminuria as urine albumin/creatinine ratio above 
300 mg/g or urine albumin excretion rate above 300 mg/
day in two consecutive measurements.
Echocardiography
Echocardiography was performed with General Electrics, 
Vivid 7 and Vivid 9 (Vingmed ultrasound, Horten, Nor-
way) and digitally stored. Three consecutive heart cycles 
were recorded for each view. The Thousand&2 echocar-
diograms (>95 %) were made by PGJ and all offline anal-
yses were performed using General Electrics EchoPac 
software BT13 by on physician (PGJ). Chamber quanti-
fication was done in accordance with the recommenda-
tions of the European Association of Echocardiography 
and the American Society of Echocardiography [20]. Left 
ventricular (LV) mass was calculated using the formula 
LV mass  =  0.8  ×  {1.04[(LV internal diameter  +  pos-
terior wall thickness  +  septal wall thickness)3  −  (LV 
internal diameter)3]}  +  0.6  g and indexed according to 
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height2.7. Left atrial (LA) end-systolic and end-diastolic 
volumes were calculated using the area-length method, 
where left atrial volume = 8/3 × π (LA area in 4 cham-
ber view × LA area in 2 chamber view/shortest long axis 
length in either view) and indexed to body surface area. 
Mitral inflow velocities [peak early (E) and peak atrial 
(A)] and deceleration time of the E wave were measured 
in the 4-chamber view using pulsed-wave Doppler with 
the sample volume placed between the tips of the mitral 
valve leaflets. Early diastolic myocardial velocity (e’) was 
measured in 4-chamber view with pulsed-wave tissue 
velocity Doppler with the sample volume placed in the 
septal and lateral mitral annulus.
Left ventricular systolic function
LV ejection fraction was assessed using Simpson’s biplane 
method. Speckle tracking echocardiography was per-
formed on 2D grey scale recordings of 4-, 2- and 3-cham-
ber apical views and analyzed off-line. In brief, the 
software identified speckles within a specified part of the 
myocardium and tracked these from frame to frame. A 
semi-automated function traced the myocardium in the 
beginning of the systole and allowed for manual modifica-
tion of the region of interest to ensure only speckles in the 
myocardium were tracked throughout the cardiac cycle. 
Visual inspection of the tracking curves ensured accurate 
tracking of the speckles and segments where the tracking 
was assessed inadequate were excluded from the analyses. 
Doing this for each segment of the left ventricle a measure-
ment of longitudinal function or deformation expressed 
as peak systolic strain was obtained for each segment and 
for 3 layers of each segment. In the present study, mid-
myocardial strain was used and global longitudinal strain 
(GLS) was calculated as the average peak systolic strain of 
the 18 midmyocardial segments. If accurate tracking was 
obtained in less than 12 of the 18 midmyocardial segments 
because of poor image quality, the echocardiogram was 
excluded from the analyses (15.3 % of the examinations). 
As a sensitivity measure to complement the strain meas-
urements of longitudinal cardiac function, longitudinal 
displacement obtained by color tissue Doppler imaging 
was performed. Longitudinal displacement was calculated 
as the average of the integral of the velocity curves during 
ejection phase of sample volumes placed in each of the 
mitral annular positions. This measure has previously been 
validated and demonstrated to be a very accurate measure 
of mitral annular plane excursion [21].
Statistics
Both the distribution of the triglyceride levels and the 
cholesterol remnant levels were markedly skewed, so 
they were logarithmically transformed in the analyses 
using the binary logarithm [log2 (triglyceride) and log2 
(cholesterol remnants)] after which both were normally 
distributed. Linear regression analyses were used to 
examine the effect of the logarithmically transformed lev-
els of triglyceride and cholesterol remnants on measures 
of cardiac structure, systolic and diastolic function. Mul-
tivariable models were constructed with age, sex, hemo-
globin A1c, body mass index, systolic blood pressure and 
albuminuria as covariates. P-values less than 0.05 on two-
sided tests were considered significant. Statistics were 
calculated using R for Mac, version 2.15.3 (R Project for 
Statistical Computing, Vienna University of Economics 
and Business Administration, Wien, Austria).
Results
A total of 924 patients were identified of whom 730 were 
receiving statin therapy. The study population’s clini-
cal and echocardiographic characteristics are shown in 
Table  1 and Additional file  1: Table S1. Notably, both 
groups and in particular the patients receiving statin 
therapy had low LDL-cholesterol levels.
Structural and diastolic measurements
Structural and diastolic echocardiographic findings of 
the entire population including patients not receiving 
statin therapy is shown in Tables 2 and 3. For all patients 
as well as the subgroup of patients receiving statin ther-
apy, increasing levels of log2 (triglyceride) were associ-
ated with increasing LV mass, LV wall thicknesses and 
decreasing LA size in univariable analyses, but this asso-
ciation was attenuated in multivariable analyses except 
for LA size. Regarding dynamic diastolic measurements, 
measures of early diastolic filling, including peak E veloc-
ity, lateral and septal e’ were only significantly associ-
ated in multivariable adjusted analyses with both log2 
(cholesterol remnant) and log2 (triglyceride). Regard-
ing LDL-cholesterol, LV wall thicknesses were inversely 
related to increasing levels of log2 (LDL-cholesterol), but 
none of the diastolic measurements were associated with 
increasing levels of log2 (LDL-cholesterol), Additional 
file  1: Table S2. A subgroup analysis of patients with 
and without known coronary heart disease showed that 
the structural and diastolic changes associated with log2 
(cholesterol remnant) and log2 (triglyceride) were driven 
by patients without known coronary heart disease. An 
exception was septal e’ that was significantly associated 
with log2(cholesterol remnants) in patients with known 
coronary heart disease whereas lateral e’ was associated 
with both log2 (cholesterol remnant) and log2 (triglycer-
ide) in patients without coronary heart disease.
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Systolic measurements
Results from echocardiographic systolic measurements 
are shown in Table 4. For all patients as well as the sub-
group of patients receiving statin therapy conventional 
measurement of systolic function in the form of ejection 
fraction by Simpson’s biplane method was not associ-
ated with neither log2 (cholesterol remnant) nor log2 
(triglyceride). However, for all patients, GLS was both 
uni- and multivariably associated with both log2 (cho-
lesterol remnants) and log2 (triglyceride). The same was 
the case for longitudinal displacement measured by color 
tissue Doppler, though the association with log2 (choles-
terol remnants) attenuated in the subgroup analysis of 
patients receiving statin therapy. Thus, two independ-
ent measurements of both LV longitudinal function both 
indicated decreased function with increasing levels of 
log2 (cholesterol remnant) and log2 (triglyceride). Similar 
results were found in the subgroup of patients receiving 
statin therapy, though some of the results were only bor-
derline significant. Regarding LDL-cholesterol, there was 
Table 1 Study population characteristics
Continuous traits are reported as mean (standard deviation) or median [interquartile range] in case of non-normal distribution
All Receiving statin therapy
n = 924 n = 730
Clinical
Age (years) 65 [58, 70] 65 [59, 70]
Male sex, n (%) 597 (65) 486 (67)
Diabetes duration (years) 11 [6, 17] 11 [6, 17]
Body mass index (kg/m2) 29 [26, 33] 30 [27, 33]
Systolic blood pressure (mmHg) 136 (17) 135 (16)
Diastolic blood pressure (mmHg) 80 (11) 80 (10)
Known coronary heart disease n (%) 162 (18) 140 (19)
Lipids
Total cholesterol (mmol/l) 4.1 [3.5, 4.8] 3.9 [3.4, 4.5]
Low density cholesterol (mmol/l) 2.0 [1.6, 2.6] 1.8 [1.5, 2.3]
High density cholesterol (mmol/l) 1.2 [1.0, 1.4] 1.2 [1.0, 1.4]
Cholesterol remnants (mmol/l) 0.8 [0.5, 1.1] 0.7 [0.5, 1.0]
Triglyceride (mmol/l) 1.7 [1.2, 2.4] 1.7 [1.2, 2.4]
Other laboratory values
Albuminuria (%) 212 (23.3) 165 (22)
 Microalbuminuria (%) 149 (16) 116 (16)
 Macroalbuminuria (%) 63 (7) 49 (7)
Creatinine (μmol/l) 78 [65, 96] 78 [66, 96]
Haemoglobin A1c (%) 55 [48, 66] 54 [48, 65]
Haemoglobin A1c (mmol/mol) 7.2 [6.5, 8.2] 7.1 [6.5, 8.1]
Medication
Statins, n (%) 730 (79) –
Metformin, n (%) 670 (73) 552 (76)
DPP4 inhibitors, n (%) 88 (10) 71 (10)
Sulfonylurea, n (%) 142 (15) 107 (15)
Glucagon‑like peptide‑1 receptor agonists, n (%) 226 (25) 189 (26)
Insulin, n (%) 428 (46) 334 (46)
Beta blockers, n (%) 221 (24) 186 (26)
Angiotensin‑converting enzyme inhibitors, n (%) 354 (38) 297 (41)
Angiotensin II receptor blockers, n (%) 359 (40) 298 (41)
Calcium antagonists, n (%) 294 (32) 250 (34)
Diuretics, n (%) 452 (49) 376 (52)
Antiplatelets, n (%) 607 (66) 508 (70)
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no association between log2 (LDL-cholesterol) and longi-
tudinal function expressed as either GLS or longitudinal 
displacement, Additional file 1: Table S2.
In a subgroup analysis of patients with and without 
known coronary heart disease, the association was both 
uni- and multivariably present only in patients without 
known coronary heart disease, Additional file  1: Tables 
S3 and S4.
Figures  1 and 2, show the predicted value with 95  % 
confidence interval of GLS and longitudinal displacement 
for increasing levels of cholesterol remnants and triglyc-
eride levels respectively on the original scale for both all 
patients and patients receiving statin therapy as well as 
the distribution of cholesterol remnant and triglyceride 
levels in all patients and patients receiving statin therapy.
Discussion
This study is the first to demonstrate that increasing lev-
els of cholesterol remnants and triglycerides—which are 
markers of cholesterol remnants—are associated with 
subtle changes in LV systolic function expressed as GLS 
and longitudinal displacement in patients with type 2 
diabetes—even when receiving statin therapy. This asso-
ciation was not present with increasing levels of LDL-
cholesterol, which was adequately treated in this patient 
population. So, even despite having treated LDL-choles-
terol to low levels, we were able to detect a relationship 
between increasing levels of cholesterol remnants and 
triglycerides and decreasing longitudinal LV function 
indicating that the detrimental effect of dyslipidemia on 
the heart is not exhausted with intensive statin therapy. 
These findings support the notion of cholesterol rem-
nants as a potential therapeutic target in addition to sta-
tin therapy in these patients.
We also found, that the association was only present in 
patients without known coronary heart disease, which 
is probably because the effect of ischemia and infarction 
overshadows the effect of the triglycerides and choles-
terol remnants on LV myocardial function or possibly 
because of lack of power in this cohort.
Table 2 Structural changes in relation to log2(cholesterol remnants) and log2(triglyceride)
Multivariable model adjusted for age, sex, hemoglobin A1c, body mass index, systolic blood pressure and albuminuria
Italic text indicates P < 0.05
log2 (cholesterol remnants) log2 (triglyceride)
Univariable Multivariable Univariable Multivariable
β-coefficient 
(std error)
P value β-coefficient  
(std error)
P value β-coefficient  
(std error)




Left ventricular mass 
index (g/m2.7)








−0.21 (0.29) 0.47 −0.47 (0.30) 0.11 −0.04 (0.26) 0.89 −0.37 (0.28) 0.18
Posterior wall  
diameter (mm)
0.16 (0.07) 0.03 0.01 (0.07) 0.90 0.25 (0.07) <0.001 0.07 (0.06) 0.28
Left atrial end  
systolic volume 
index (ml/m2)
−1.61 (0.39) <0.001 −1.41 (0.41) 0.001 −1.29 (0.35) <0.001 −1.19 (0.37) 0.002
In patients receiving statin therapy
Left ventricular mass 
index (g/m2.7)




0.22 (0.09) 0.02 0.04 (0.09) 0.67 0.29 (0.09) <0.001 0.08 (0.08) 0.35
End diastolic internal 
diameter (mm)
−0.30 (0.33) 0.36 −0.58 (0.34) 0.08 −0.17 (0.30) 0.57 −0.53 (0.31) 0.09
Posterior wall  
diameter (mm)
0.17 (0.08) 0.04 0.04 (0.08) 0.62 0.26 (0.07) <0.001 0.10 (0.07) 0.17
Left atrial end  
systolic volume 
index (ml/m2)
−1.73 (0.45) <0.001 −1.47 (0.47) 0.002 −1.44 (0.40) <0.001 −1.33 (0.43) 0.002
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Dyslipidemia, LV changes and risk of heart failure
Animal models have linked cholesterol levels with 
changes in both diastolic and systolic performance [22, 
23] and one study found an association with LV ejec-
tion fraction and HDL-cholesterol in patients with 
angina pectoris [24]. In a recent paper, Mochizuki et al. 
Table 3 Diastolic changes in relation to log2(cholesterol remnants) and log2(triglyceride) in patients with type 2 diabetes
Multivariable model adjusted for age, sex, hemoglobin A1c, body mass index, systolic blood pressure and albuminuria
Italic text indicates P < 0.05
log2 (cholesterol remnants) log2 (triglyceride)
Univariable Multivariable Univariable Multivariable
β-coefficient  
(std error)
P value β-coefficient  
(std error)
P value β coefficient  
(std error)




Peak E velocity (m/s) −0.01 (0.01) 0.12 −0.03 (0.01) 0.006 −0.01 (0.01) 0.09 −0.03 (0.01) 0.002
Peak A velocity (m/s) −0.003 (0.01) 0.76 −0.001 (0.01) 0.93 −0.01 (0.01) 0.51 −0.003 (0.01) 0.72
E/A ratio −0.01 (0.01) 0.48 −0.03 (0.01) 0.05 −0.01 (0.01) 0.53 −0.03 (0.01) 0.03
E deceleration time 
(ms)
2.8 (3.5) 0.41 3.3 (3.6) 0.36 0.8 (3.1) 0.81 1.5 (3.3) 0.65
Lateral e’ (cm/s) −0.18 (0.12) 0.13 −0.25 (0.11) 0.02 −0.19 (0.11) 0.07 −0.27 (0.10) 0.008
Septal e’ (cm/s) −0.12 (0.09) 0.19 −0.18 (0.08) 0.03 −0.10 (0.08) 0.22 −0.17 (0.08) 0.03
E/e’mean 0.11 (0.20) 0.58 0.01 (0.20) 0.97 0.08 (0.18) 0.65 −0.02 (0.18) 0.93
Patients receiving statin therapy
Peak E velocity 
(cm/s)
−0.02 (0.01) 0.08 −0.03 (0.01) 0.006 −0.02 (0.01) 0.08 −0.03 (0.01) 0.004
Peak A velocity 
(cm/s)
−0.002 (0.01) 0.82 −0.0003 (0.01) 0.98 −0.01 (0.01) 0.57 −0.002 (0.01) 0.86
E/A ratio −0.02 (0.01) 0.25 −0.03 (0.01) 0.02 −0.01 (0.01) 0.36 −0.03 (0.01) 0.02
E deceleration time 
(ms)
3.8 (3.9) 0.33 3.57 (4.11) 0.39 1.3 (3.5) 0.72 1.1 (3.7) 0.77
Lateral e’ (cm/s) −0.07 (0.13) 0.59 −0.19 (0.13) 0.13 −0.10 (0.12) 0.37 −0.21 (0.11) 0.07
Septal e’ (cm/s) −0.07 (0.10) 0.49 −0.17 (0.10) 0.08 −0.10 (0.09) 0.27 −0.18 (0.09) 0.04
E/e’mean −0.10 (0.22) 0.65 −0.17 (0.22) 0.44 −0.06 (0.20) 0.78 −0.13 (0.20) 0.53
Table 4 Systolic changes in relation to log2(cholesterol remnants) and log2(triglyceride) in patients with type 2 diabetes
Multivariable model adjusted for age, sex, hemoglobin A1c, body mass index, systolic blood pressure and albuminuria
Italic text indicates P < 0.05
log2 (cholesterol remnants) log2 (triglyceride)
Univariable Multivariable Univariable Multivariable
β-coefficient  
(std error)
P value β-coefficient  
(std error)
P value β-coefficient  
(std error)




Ejection fraction (%) −0.7 (0.4) 0.09 −0.4 (0.4) 0.31 −0.6 (0.4) 0.09 −0.3 (0.4) 0.42
Global longitudinal 
systolic strain (%)
0.40 (0.13) 0.003 0.33 (0.14) 0.02 0.34 (0.12) 0.004 0.28 (0.13) 0.03
Longitudinal dis‑
placement (mm)
−0.25 (0.09) 0.007 −0.25 (0.10) 0.01 −0.25 (0.08) 0.003 −0.25 (0.09) 0.005
Patients receiving statin therapy
Ejection fraction (%) −0.7 (0.4) 0.12 −0.4 (0.5) 0.43 −0.5 (0.4) 0.18 −0.1 (0.4) 0.72
Global longitudinal 
systolic strain (%)
0.38 (0.15) 0.01 0.32 (0.16) 0.05 0.33 (0.14) 0.01 0.29 (0.15) 0.05
Longitudinal dis‑
placement (mm)
−0.20 (0.11) 0.07 −0.20 (0.11) 0.06 −0.22 (0.09) 0.02 −0.22 (0.10) 0.03
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Fig. 1 Association of cholesterol remnants levels to global longitudinal strain and longitudinal displacement in patients with type 2 diabetes and 
in patients with type 2 diabetes receiving statin therapy. The upper curves depict the predicted value with 95 % confidence interval of GLS and lon‑
gitudinal displacement for increasing levels of cholesterol remnants on the original scale for both all patients and patients receiving statin therapy. 
The lower histograms are the distribution of cholesterol remnants in all patients and patients receiving statin therapy. Cholesterol remnants were 
calculated by total‑cholesterol − HDL‑cholesterol − LDL‑cholesterol
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[25] studied the clinical features of decreased GLS in 
144 patients with diabetes and found that among oth-
ers hypertriglyceridemia was closely associated with 
low GLS. In patients with hypertension, hypercholes-
terolemia and low levels of HDL-cholesterol have been 
linked to increased LV mass [26, 27], and—in a mixed 
Fig. 2 Association of triglyceride levels to global longitudinal strain and longitudinal displacement in patients with type 2 diabetes and in patients 
with type 2 diabetes receiving statin therapy. The upper curves depict the predicted value with 95 % confidence interval of GLS and longitudinal 
displacement for increasing levels of triglycerides on the original scale for both all patients and patients receiving statin therapy. The lower histo‑
grams are the distribution of triglycerides in all patients and patients receiving statin therapy
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population—high levels of triglyceride were associ-
ated with increased LV mass index and decreased dias-
tolic function expressed as lower e’, E/A ratio and longer 
deceleration time and isovolumetric relaxation time [28]. 
In accordance with these studies, we found increased 
LV mass with increasing levels of triglyceride (that is 
inversely related to HDL-cholesterol), which however, 
was attenuated when performing multivariable adjust-
ment. The opposite was the case, in the diastolic meas-
urements, where we only found changes in e’, peak E 
velocity and E/A ratio after multivariable adjustment. 
These differences may be explained by differences in 
patient populations and/or because of categorical cut-
offs whereas we used continuous.
The influence of lipid levels on cardiac structure and 
incident heart failure has also been examined in the 
Framingham cohort. Though they did find a strong rela-
tionship between both non-HDL- and HDL-cholesterol 
levels and risk of heart failure in this population [29], 
they concluded, that there was no meaningful relation-
ship between changes in LV structure and lipid levels. 
However, they did not examine any functional changes in 
the form of diastolic and systolic measurements [30]. In 
conclusion, our study is mainly in accordance with pre-
vious studies reporting a weak association of lipid levels 
and LV structure and diastolic function. In addition, our 
results suggests that the increased risk of heart failure 
related to dyslipidemia may be demonstrated in an early 
phase using sensitive measures of LV function including 
GLS and longitudinal displacement.
Cholesterol remnants, triglycerides and longitudinal 
dysfunction as marker of early ischemic heart disease?
Remnant lipoproteins are thought to cause atherosclero-
sis by mechanisms similar to LDL-cholesterol, which is 
by entering and accumulating in the intima of the arterial 
wall [7, 8], ultimately leading to coronary occlusion. Con-
sequently, a number of studies have assigned an increased 
risk of coronary heart disease with increasing levels of 
triglycerides/cholesterol remnants [13, 31, 32]. However, 
as this is a slowly progressing process, it is likely, that only 
partial occlusion of the coronary arteries is present in the 
early stages of the disease affecting primarily the oxygen 
delivery to the distal parts of the coronary arteries. Here, 
in the subendocardial myofiber band, is where the longi-
tudinal myocardial fibers are situated, and hence, the lon-
gitudinal function is thought to be the first to be affected 
in coronary atherosclerosis [9]. Therefore, measures of 
longitudinal function like GLS and longitudinal displace-
ment are considered to be sensitive markers of early signs 
of the impact of atherosclerosis on cardiac function [33]. 
This is consistent with our findings where increasing 
levels of both triglyceride and cholesterol remnants were 
associated with decreasing longitudinal function, and in 
this light, it is possible that subclinical atherosclerosis 
in patients with high levels of cholesterol remnants and 
triglycerides is part of the explanation to the decreased 
longitudinal function we found in patients with type 2 
diabetes. This is further supported by Wei et al. [34], who 
recently proposed myocardial steatosis as a mechanistic 
link between diastolic dysfunction and coronary micro-
vascular dysfunction in women.
Cholesterol remnants, triglycerides and accumulation 
of myocardial triglycerides
At least one other mechanism may lead to decreased 
myocardial function with increasing levels of triglyc-
erides and cholesterol remnants. In type 2 diabetes, 
excess availability of free fatty acids in the myocardium 
shifts the substrate for metabolism to almost entirely 
to rely on oxidation of free fatty acids, which in turn is 
thought to be a major cause of diabetic cardiomyopa-
thy, that is, left ventricular impairment in patients with 
diabetes in the absence of coronary artery disease and 
hypertension [35]. Triglycerides are cleaved on the sur-
face of lipoprotein remnants by the action of lipoprotein 
lipase present either in the endothelium or the intima of 
the coronary arteries [10]. In accordance, cardiac stea-
tosis as measured by cardiac magnetic resonance spec-
troscopy has been shown to be present in patients with 
diabetes [36], and to be associated both with impairment 
in diastolic function [37] and systolic function expressed 
as decreased GLS with normal ejection fraction [38]. In 
addition, a study by Hammer et al. [39] showed that pro-
longed caloric restriction in obese patients with type 2 
diabetes decreased myocardial triglyceride content and 
improved diastolic heart function. Also, this was accom-
panied by a decrease in fasting plasma-triglyceride and 
total-cholesterol levels. Taken together, these findings are 
very consistent with our findings that demonstrated dete-
rioration of both diastolic (however vague) and systolic 
function with increasing levels of cholesterol remnants 
and triglyceride levels.
Strengths and limitations
This study is strong, in that it is a large cohort of patients 
with type 2 diabetes which is very well characterized 
with clinical characteristics, laboratory values and com-
prehensive echocardiography. Also, sample size is suffi-
ciently large to perform sub-analyses of patients without 
known heart disease and—in particular—patients 
receiving statin therapy. However, the study has some 
limitations. Though the majority of patients had non-
fasting lipid measurements a minority only had fasting 
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lipids available. However, the association persisted when 
excluding patients with fasting lipid measurements from 
the analyses. Also, as this is an observational study, it is 
not possible to entirely rule out residual confounding.
Conclusions
In patients with type 2 diabetes, subtle decrease in left ven-
tricular function is present with increasing levels of choles-
terol remnants and triglyceride levels indicating an effect of 
these on cardiac function that is not detectable by conven-
tional echocardiography. This association is present even 
in patients that are adequately treated with statin therapy. 
These findings support the notion of cholesterol remnants 
as possible therapeutic target in addition to statin therapy.
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